![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for type II diabetes and obesity because of its pivotal role as a negative modulator in both insulin and leptin signalling pathways.
Objective: The discovery of PTP1B inhibitors has been the focus of researchers in both academia and pharmaceutical industry over the last two decades.
Results and Conclusion: Though, intense pharmaceutical research in this area has resulted in many potent PTP1B inhibitors, a vast majority of them possessed pTyr mimetic group such as phosphonates, carboxylic acids and sulphamic acids, which led to poor PTP1B selectivity and insufficient in vivo efficacy due to low cell permeability and bioavailability. The availability of X-ray crystallographic structures of PTP1B together with the application of molecular modelling and other innovative strategies led to the development of many potent and selective PTP1B inhibitors with desirable physicochemical properties. This review traces the development of PTP1B inhibitors over the last decade and also records novel PTP1B inhibitors developed recently with greater emphasis on their selectivity and cell permeability.
Keywords: Diabetes, obesity, PTP1B inhibitors, molecular modelling, drug discovery, signalling pathways.
Current Drug Targets
Title:Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity
Volume: 19 Issue: 5
Author(s): Neelesh Maheshwari, Chandrabose Karthikeyan, Piyush Trivedi and N.S. Hari Narayana Moorthy*
Affiliation:
- Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak (MP)-484887,India
Keywords: Diabetes, obesity, PTP1B inhibitors, molecular modelling, drug discovery, signalling pathways.
Abstract: Background: Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for type II diabetes and obesity because of its pivotal role as a negative modulator in both insulin and leptin signalling pathways.
Objective: The discovery of PTP1B inhibitors has been the focus of researchers in both academia and pharmaceutical industry over the last two decades.
Results and Conclusion: Though, intense pharmaceutical research in this area has resulted in many potent PTP1B inhibitors, a vast majority of them possessed pTyr mimetic group such as phosphonates, carboxylic acids and sulphamic acids, which led to poor PTP1B selectivity and insufficient in vivo efficacy due to low cell permeability and bioavailability. The availability of X-ray crystallographic structures of PTP1B together with the application of molecular modelling and other innovative strategies led to the development of many potent and selective PTP1B inhibitors with desirable physicochemical properties. This review traces the development of PTP1B inhibitors over the last decade and also records novel PTP1B inhibitors developed recently with greater emphasis on their selectivity and cell permeability.
Export Options
About this article
Cite this article as:
Maheshwari Neelesh, Karthikeyan Chandrabose, Trivedi Piyush and Moorthy Hari Narayana N.S.*, Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450118666170222143739
DOI https://dx.doi.org/10.2174/1389450118666170222143739 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Current Vascular Pharmacology Evaluation of Hyperforin Analogues for Inhibition of 5-lipoxygenase
Medicinal Chemistry Protective Effects of <i>Dendrobium nobile</i> Lindl. Alkaloids on Alzheimer's Disease-like Symptoms Induced by High-methionine Diet
Current Neuropharmacology Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis
Current Drug Therapy New Technological Developments in the Clinical Imaging of Atherosclerotic Plaque
Current Pharmaceutical Design Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Potential Therapeutic Drugs and Methods for the Treatment of Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Screening and Identification of Differentially Expressed Genes Between Diabetic Nephropathy Glomerular and Normal Glomerular via Bioinformatics Technology
Combinatorial Chemistry & High Throughput Screening Network based Approach to Drug Discovery: A Mini Review
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Protective Effect of Dietary Potassium against Cardiovascular Damage in Salt-Sensitive Hypertension: Possible Role of its Antioxidant Action
Current Vascular Pharmacology A Review on Recent Developments in Positron Emission Tomography Technology
Recent Patents on Medical Imaging